EWA
SLN

EverSource Wealth Advisors’s Silence Therapeutics SLN Stock Holding History

EverSource Wealth Advisors’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10
Closed -$58 – 4458
2025
Q2 		$58 Buy
+10
New +$43 ﹤0.01% 4181

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return

EverSource Wealth Advisors's SLN Position: Q3 2025 in Review

EverSource Wealth Advisors sold out of Silence Therapeutics (SLN) in Q3 2025, closing a stake of 10 shares — an estimated $58 sold.

EverSource Wealth Advisors first reported a position in SLN in Q2 2025 and held it in 1 quarter. The position peaked at $58 in Q2 2025. 54 funds tracked by Wall St. Rank hold SLN as of Q3 2025.

  • EverSource Wealth Advisors reported no remaining Silence Therapeutics position as of Q3 2025 after selling out during the quarter.
  • EverSource Wealth Advisors sold 10 Silence Therapeutics shares in Q3 2025, an estimated $58.
  • EverSource Wealth Advisors first reported a position in Silence Therapeutics in Q2 2025 and held it in 1 quarter.
  • EverSource Wealth Advisors's Silence Therapeutics position peaked at $58 in Q2 2025.
  • 54 funds tracked by Wall St. Rank held Silence Therapeutics as of Q3 2025.

Based on EverSource Wealth Advisors's 13F filing for Q3 2025, filed 10 Nov 2025.